Mitchell de Long
Corporate Officer/Principal chez AERIE PHARMACEUTICALS, INC.
Profil
Mitchell A.
de Long is currently working as the Vice President-Chemistry at Aerie Pharmaceuticals, Inc. He previously worked as a Research Scientist at Procter & Gamble Co. Dr. de Long holds a doctorate degree from Stanford University.
Postes actifs de Mitchell de Long
| Sociétés | Poste | Début |
|---|---|---|
| AERIE PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/01/2005 |
Anciens postes connus de Mitchell de Long
| Sociétés | Poste | Fin |
|---|---|---|
| PROCTER & GAMBLE COMPANY | Directeur Technique/Scientifique/R&D | - |
Formation de Mitchell de Long
| Stanford University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PROCTER & GAMBLE COMPANY | Consumer Non-Durables |
| Entreprise privées | 1 |
|---|---|
Aerie Pharmaceuticals, Inc.
 Aerie Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on January 1, 2005 and is headquartered in Durham, NCForth Worth, TX. | Health Technology |
